
Inventiva S.A. (IVA) Stock Forecast & Price Target
Inventiva S.A. (IVA) Analyst Ratings
Bulls say
Inventiva SA, a France-based biopharmaceutical company, is advancing its candidate lanifibranor for the treatment of non-alcoholic steatohepatitis (NASH), a condition with no current approved therapies, which positions the company favorably within an unmet medical need segment. Positive clinical outcomes have been observed with lanifibranor improving critical metabolic markers such as HbA1c and triglycerides while demonstrating significant fibrosis improvement in trial metrics, suggesting its potential as a leading therapy in the evolving NASH treatment landscape. Furthermore, collaboration partnerships with AbbVie and BI drive the majority of Inventiva's revenue, reinforcing their financial stability and supporting ongoing research initiatives in key therapeutic areas.
Bears say
Inventiva SA has reported a significant net loss of €175.9 million, or €1.62 per share, highlighting underlying financial challenges that may adversely affect shareholder confidence. The primary clinical program, lanifibranor, is in Phase III development, and any efficacy or safety concerns that arise during this phase could substantially diminish stock performance. Additionally, the company faces multiple risks, including potential clinical trial failures, delays in development timelines, and difficulties accessing equity capital markets, which could further jeopardize its operational viability and financial stability.
This aggregate rating is based on analysts' research of Inventiva S.A. and is not a guaranteed prediction by Public.com or investment advice.
Inventiva S.A. (IVA) Analyst Forecast & Price Prediction
Start investing in Inventiva S.A. (IVA)
Order type
Buy in
Order amount
Est. shares
0 shares